Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of ILT-101 (low-dose IL-2) in moderate to severe systemic lupus erythematosus
2016-000488-17Phase 2Completed
- Sponsor
- ILTOO Pharma
- Start
- Jul 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing ILT-101 with Placebo (2 arms). Primary endpoint: SRI-4 response at week 12. Started Jul 2016; status: completed.
02
Drugs
aldesleukin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2016-000488-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000488-17.